EM-800

EM-800, an orally active anti-estrogen, serves as an antagonist to the transcriptional functions of estrogen receptors α (ERα) and β (ERβ) . EM-800 possesses anticancer activity, capable of inhibiting the growth of breast cancer induced by 7,12-Dimethylbenz[a]anthracene (DMBA) (HY-W011845) . Furthermore, in ovariectomized animals, EM-800 effectively slows down bone loss. Additionally, EM-800 shows potential in the research of breast and endometrial cancers, while exerting beneficial effects on bone and lipid metabolism[1][2].

Product Specifications

CAS Number

[182167-03-9]

UNSPSC

12352005

Target

Estrogen Receptor/ERR

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/em-800.html

Smiles

CC(C)(C(OC1=CC2=C(C(C)=C([C@@H](O2)C3=CC=C(C=C3)OCCN4CCCCC4)C5=CC=C(C=C5)OC(C(C)(C)C)=O)C=C1)=O)C

Molecular Formula

C39H47NO6

Molecular Weight

625.79

References & Citations

[1]Tremblay A, et al. EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors alpha and beta. Endocrinology. 1998 Jan;139 (1) :111-8.|[2]Labrie F, et al. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Mol Biol. 1999 Apr-Jun;69 (1-6) :51-84.